These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 26408258

  • 21. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M, Abnous K, Mohammadi M, Hadizadeh F, Sadeghi F, Taghavi S, Jaafari MR, Ramezani M.
    J Control Release; 2017 Oct 28; 264():228-236. PubMed ID: 28844758
    [Abstract] [Full Text] [Related]

  • 22. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.
    Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD.
    Cancer Immunol Res; 2015 May 28; 3(5):526-35. PubMed ID: 25627655
    [Abstract] [Full Text] [Related]

  • 23. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
    Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL.
    Gynecol Oncol; 2016 May 28; 141(2):357-363. PubMed ID: 26946092
    [Abstract] [Full Text] [Related]

  • 24. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.
    Clin Cancer Res; 2009 Mar 01; 15(5):1623-34. PubMed ID: 19208793
    [Abstract] [Full Text] [Related]

  • 25. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
    Dubrot J, Palazón A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, Hervás-Stubbs S, Melero I.
    Int J Cancer; 2011 Jan 01; 128(1):105-18. PubMed ID: 20309938
    [Abstract] [Full Text] [Related]

  • 26. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg S.
    Cancer Immunol Res; 2018 Jan 01; 6(1):59-68. PubMed ID: 29122838
    [Abstract] [Full Text] [Related]

  • 27. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.
    Hattori Y, Shibuya K, Kojima K, Miatmoko A, Kawano K, Ozaki K, Yonemochi E.
    Int J Oncol; 2015 Jul 01; 47(1):211-9. PubMed ID: 25955490
    [Abstract] [Full Text] [Related]

  • 28. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.
    Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, Fiers W, ten Hagen TL.
    Int J Cancer; 2004 Apr 10; 109(3):442-8. PubMed ID: 14961585
    [Abstract] [Full Text] [Related]

  • 29. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M, Tagawa T, Wu L, Yun Z, Keshavjee S, Zhang L, Johnston MR, de Perrot M.
    J Immunol; 2010 Jul 15; 185(2):956-66. PubMed ID: 20548032
    [Abstract] [Full Text] [Related]

  • 30. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.
    J Immunother; 2012 May 15; 35(4):344-53. PubMed ID: 22495392
    [Abstract] [Full Text] [Related]

  • 31. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A.
    Clin Cancer Res; 1998 Feb 15; 4(2):499-505. PubMed ID: 9516942
    [Abstract] [Full Text] [Related]

  • 32. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
    Evans EE, Jonason AS, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, Fisher TL, Bowers WJ, Paris M, Smith ES, Zauderer M.
    Cancer Immunol Res; 2015 Jun 15; 3(6):689-701. PubMed ID: 25614511
    [Abstract] [Full Text] [Related]

  • 33. Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice.
    Yahuafai J, Asai T, Oku N, Siripong P.
    Biol Pharm Bull; 2018 Jun 15; 41(7):1103-1106. PubMed ID: 29962406
    [Abstract] [Full Text] [Related]

  • 34. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.
    Cancer Chemother Pharmacol; 2010 May 15; 66(1):43-52. PubMed ID: 19779718
    [Abstract] [Full Text] [Related]

  • 35. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
    John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.
    Clin Cancer Res; 2013 Oct 15; 19(20):5636-46. PubMed ID: 23873688
    [Abstract] [Full Text] [Related]

  • 36. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
    Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A.
    Cancer Res; 2004 Oct 01; 64(19):7150-5. PubMed ID: 15466213
    [Abstract] [Full Text] [Related]

  • 37. Synergistic apoptotic effect of Doxil ® and aminolevulinic acid-based photodynamic therapy on human breast adenocarcinoma cells.
    Zakaria S, Gamal-Eldeen AM, El-Daly SM, Saleh S.
    Photodiagnosis Photodyn Ther; 2014 Jun 01; 11(2):227-38. PubMed ID: 24632331
    [Abstract] [Full Text] [Related]

  • 38. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
    Zhao Y, Alakhova DY, Kim JO, Bronich TK, Kabanov AV.
    J Control Release; 2013 May 28; 168(1):61-9. PubMed ID: 23474033
    [Abstract] [Full Text] [Related]

  • 39. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA.
    J Oncol Pharm Pract; 2007 Mar 28; 13(1):39-45. PubMed ID: 17621566
    [Abstract] [Full Text] [Related]

  • 40. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Hubert P, Roncarati P, Demoulin S, Pilard C, Ancion M, Reynders C, Lerho T, Bruyere D, Lebeau A, Radermecker C, Meunier M, Nokin MJ, Hendrick E, Peulen O, Delvenne P, Herfs M.
    J Immunother Cancer; 2021 Mar 28; 9(3):. PubMed ID: 33712445
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.